Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas

Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating b-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2007-02, Vol.26 (5), p.774-780
Hauptverfasser: Zucman-Rossi, J, Benhamouche, S, Godard, C, Boyault, S, Grimber, G, Balabaud, C, Cunha, A S, Bioulac-Sage, P, Perret, C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 780
container_issue 5
container_start_page 774
container_title Oncogene
container_volume 26
creator Zucman-Rossi, J
Benhamouche, S
Godard, C
Boyault, S
Grimber, G
Balabaud, C
Cunha, A S
Bioulac-Sage, P
Perret, C
description Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating b-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of b-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, b-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. b-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in b-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of b-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.Oncogene (2007) 26, 774-780. doi:10.1038/sj.onc.1209824; published online 11 September 2006
doi_str_mv 10.1038/sj.onc.1209824
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_21310864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21310864</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_213108643</originalsourceid><addsrcrecordid>eNqNi7tOxDAQRV2AtMujpZ6KLmHsLJCUiIf4APrV4J1oZ-WMl4yN-HyChERLc8_V1T3OXXlsPXb9jR3arLH1AYc-bE7cGodbbIbQhZU7Mzsg4v2AYe30ScaRZ9YilICXHotBHkGUYpFPKryDhy9RD6Q7-Nvem7hQRWGqhYpktcWBfZ1oST5SyZFTqolmiDRH0TyRXbjTkZLx5S_P3fXL89vja3Oc80dlK9tJ7Mcj5VxtG3znsb_bdP8-fgM9eFLT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21310864</pqid></control><display><type>article</type><title>Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas</title><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zucman-Rossi, J ; Benhamouche, S ; Godard, C ; Boyault, S ; Grimber, G ; Balabaud, C ; Cunha, A S ; Bioulac-Sage, P ; Perret, C</creator><creatorcontrib>Zucman-Rossi, J ; Benhamouche, S ; Godard, C ; Boyault, S ; Grimber, G ; Balabaud, C ; Cunha, A S ; Bioulac-Sage, P ; Perret, C</creatorcontrib><description>Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating b-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of b-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, b-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. b-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in b-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of b-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.Oncogene (2007) 26, 774-780. doi:10.1038/sj.onc.1209824; published online 11 September 2006</description><identifier>ISSN: 0950-9232</identifier><identifier>DOI: 10.1038/sj.onc.1209824</identifier><language>eng</language><ispartof>Oncogene, 2007-02, Vol.26 (5), p.774-780</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Zucman-Rossi, J</creatorcontrib><creatorcontrib>Benhamouche, S</creatorcontrib><creatorcontrib>Godard, C</creatorcontrib><creatorcontrib>Boyault, S</creatorcontrib><creatorcontrib>Grimber, G</creatorcontrib><creatorcontrib>Balabaud, C</creatorcontrib><creatorcontrib>Cunha, A S</creatorcontrib><creatorcontrib>Bioulac-Sage, P</creatorcontrib><creatorcontrib>Perret, C</creatorcontrib><title>Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas</title><title>Oncogene</title><description>Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating b-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of b-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, b-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. b-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in b-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of b-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.Oncogene (2007) 26, 774-780. doi:10.1038/sj.onc.1209824; published online 11 September 2006</description><issn>0950-9232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNi7tOxDAQRV2AtMujpZ6KLmHsLJCUiIf4APrV4J1oZ-WMl4yN-HyChERLc8_V1T3OXXlsPXb9jR3arLH1AYc-bE7cGodbbIbQhZU7Mzsg4v2AYe30ScaRZ9YilICXHotBHkGUYpFPKryDhy9RD6Q7-Nvem7hQRWGqhYpktcWBfZ1oST5SyZFTqolmiDRH0TyRXbjTkZLx5S_P3fXL89vja3Oc80dlK9tJ7Mcj5VxtG3znsb_bdP8-fgM9eFLT</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Zucman-Rossi, J</creator><creator>Benhamouche, S</creator><creator>Godard, C</creator><creator>Boyault, S</creator><creator>Grimber, G</creator><creator>Balabaud, C</creator><creator>Cunha, A S</creator><creator>Bioulac-Sage, P</creator><creator>Perret, C</creator><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20070201</creationdate><title>Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas</title><author>Zucman-Rossi, J ; Benhamouche, S ; Godard, C ; Boyault, S ; Grimber, G ; Balabaud, C ; Cunha, A S ; Bioulac-Sage, P ; Perret, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_213108643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zucman-Rossi, J</creatorcontrib><creatorcontrib>Benhamouche, S</creatorcontrib><creatorcontrib>Godard, C</creatorcontrib><creatorcontrib>Boyault, S</creatorcontrib><creatorcontrib>Grimber, G</creatorcontrib><creatorcontrib>Balabaud, C</creatorcontrib><creatorcontrib>Cunha, A S</creatorcontrib><creatorcontrib>Bioulac-Sage, P</creatorcontrib><creatorcontrib>Perret, C</creatorcontrib><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zucman-Rossi, J</au><au>Benhamouche, S</au><au>Godard, C</au><au>Boyault, S</au><au>Grimber, G</au><au>Balabaud, C</au><au>Cunha, A S</au><au>Bioulac-Sage, P</au><au>Perret, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas</atitle><jtitle>Oncogene</jtitle><date>2007-02-01</date><risdate>2007</risdate><volume>26</volume><issue>5</issue><spage>774</spage><epage>780</epage><pages>774-780</pages><issn>0950-9232</issn><abstract>Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating b-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of b-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, b-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. b-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in b-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of b-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.Oncogene (2007) 26, 774-780. doi:10.1038/sj.onc.1209824; published online 11 September 2006</abstract><doi>10.1038/sj.onc.1209824</doi></addata></record>
fulltext fulltext
identifier ISSN: 0950-9232
ispartof Oncogene, 2007-02, Vol.26 (5), p.774-780
issn 0950-9232
language eng
recordid cdi_proquest_miscellaneous_21310864
source Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings
title Differential effects of inactivated Axin1 and activated b-catenin mutations in human hepatocellular carcinomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T14%3A14%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20effects%20of%20inactivated%20Axin1%20and%20activated%20b-catenin%20mutations%20in%20human%20hepatocellular%20carcinomas&rft.jtitle=Oncogene&rft.au=Zucman-Rossi,%20J&rft.date=2007-02-01&rft.volume=26&rft.issue=5&rft.spage=774&rft.epage=780&rft.pages=774-780&rft.issn=0950-9232&rft_id=info:doi/10.1038/sj.onc.1209824&rft_dat=%3Cproquest%3E21310864%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21310864&rft_id=info:pmid/&rfr_iscdi=true